Whelan Aviva J, Mim Sabiha, Hunt J Porter, McKnite Autumn M, Green Danielle J, Imburgia Carina E, Momper Jeremiah D, Stitt Gideon, Watt Kevin M
Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA - Division of Pediatric Critical Care, Department of Pediatrics, University of Utah, 295 Chipeta Way, Salt Lake City, UT 84108, USA.
Pharmacometric Research Group, Department of Pharmacy, Uppsala University, Husargatan, Uppsala 752 37, Sweden.
J Extra Corpor Technol. 2024 Dec;56(4):167-173. doi: 10.1051/ject/2024014. Epub 2024 Dec 20.
Milrinone is commonly prescribed to critically ill patients who need extracorporeal life support such as extracorporeal membrane oxygenation (ECMO) and continuous renal replacement therapy (CRRT). Currently, the effect of ECMO and CRRT on the disposition of milrinone is unknown.
Ex vivo ECMO and CRRT circuits were primed with human blood and then dosed with milrinone to study drug extraction by the circuits. Milrinone percent recovery over time was calculated to determine circuit component interaction with milrinone.
Milrinone did not exhibit measurable interactions with the ECMO circuit, however, CRRT cleared 99% of milrinone from the experimental circuit within the first 2 hours.
Milrinone dosing adjustments are likely required in patients who are supported with CRRT while dosing adjustments for ECMO based on these ex-vivo results are likely unnecessary. These results will help improve the safety and efficacy of milrinone in patients requiring ECMO and CRRT. Due to the limitations of ex-vivo experiments, future studies of milrinone exposure with ECLS should include patient circuit interactions as well as the physiology of critical illness.
米力农常用于需要体外生命支持(如体外膜肺氧合(ECMO)和持续肾脏替代治疗(CRRT))的危重症患者。目前,ECMO和CRRT对米力农处置的影响尚不清楚。
用人体血液预充体外ECMO和CRRT回路,然后给予米力农以研究回路对药物的提取作用。计算米力农随时间的回收率,以确定回路组件与米力农的相互作用。
米力农与ECMO回路未表现出可测量的相互作用,然而,CRRT在最初2小时内从实验回路中清除了99%的米力农。
接受CRRT支持的患者可能需要调整米力农剂量,而基于这些体外实验结果对ECMO进行剂量调整可能没有必要。这些结果将有助于提高米力农在需要ECMO和CRRT的患者中的安全性和有效性。由于体外实验的局限性,未来关于米力农在体外膜肺氧合支持下暴露情况的研究应包括患者与回路的相互作用以及危重症的生理学情况。